Loading…
MiniMed Group, Inc.
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
Company description provided by Yahoo Finance.